Moderna (MRNA)
(Delayed Data from NSDQ)
$118.32 USD
+2.37 (2.04%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $118.20 -0.12 (-0.10%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
MRNA 118.32 +2.37(2.04%)
Will MRNA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRNA
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
MRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine
CDC Narrows Age Recommendation for Use of RSV Vaccine
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
Other News for MRNA
Tesla, Archer Aviation rise; Eli Lilly falls, Tuesday, 7/2/2024
The US will pay Moderna $176 million to develop an mRNA pandemic flu vaccine
US will pay vaccine maker Moderna $176 million to develop an mRNA-based pandemic flu vaccine
IN BRIEF: Moderna gets EMA marketing nod for mResvia vaccine
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet